Immunovant (IMVT) Competitors $16.11 -0.44 (-2.66%) Closing price 04:00 PM EasternExtended Trading$16.06 -0.05 (-0.34%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, RVMD, and GRFSShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Grifols (GRFS). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics Viatris Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment. Which has higher earnings and valuation, IMVT or SLNO? Soleno Therapeutics has higher revenue and earnings than Immunovant. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.65Soleno Therapeutics$32.66M101.08-$175.85M-$4.14-15.00 Do analysts recommend IMVT or SLNO? Immunovant presently has a consensus price target of $33.20, indicating a potential upside of 106.08%. Soleno Therapeutics has a consensus price target of $115.92, indicating a potential upside of 86.63%. Given Immunovant's higher possible upside, equities analysts plainly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93 Is IMVT or SLNO more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Soleno Therapeutics N/A -73.74%-56.67% Does the media prefer IMVT or SLNO? In the previous week, Soleno Therapeutics had 8 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Soleno Therapeutics and 2 mentions for Immunovant. Soleno Therapeutics' average media sentiment score of 0.08 beat Immunovant's score of -0.06 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Soleno Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, IMVT or SLNO? Immunovant has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, meaning that its stock price is 375% less volatile than the S&P 500. Do institutionals and insiders have more ownership in IMVT or SLNO? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummarySoleno Therapeutics beats Immunovant on 10 of the 14 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81B$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-5.6521.5485.6826.86Price / SalesN/A422.92582.47185.05Price / CashN/A46.3226.3031.10Price / Book3.8710.0613.246.72Net Income-$413.84M-$52.22M$3.30B$276.35M7 Day Performance-0.06%5.85%4.67%3.10%1 Month Performance-6.01%12.06%8.40%10.19%1 Year Performance-45.20%26.14%88.01%40.34% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.8844 of 5 stars$16.11-2.7%$33.20+106.1%-45.8%$2.81BN/A-5.65120SLNOSoleno Therapeutics4.414 of 5 stars$68.16+4.9%$115.09+68.9%+17.8%$3.45BN/A-16.4630Analyst ForecastGap UpVTRSViatris1.783 of 5 stars$9.62+1.1%$10.40+8.1%-12.6%$11.10B$14.74B-3.3232,000ROIVRoivant Sciences3.5032 of 5 stars$15.10-0.5%$19.94+32.0%+42.9%$10.36B$23.23M-21.57860QGENQIAGEN4.4532 of 5 stars$43.880.0%$49.69+13.2%+10.9%$9.76B$1.98B25.935,765ELANElanco Animal Health2.5853 of 5 stars$19.63+0.1%$18.33-6.6%+41.1%$9.74B$4.44B22.829,000News CoverageAnalyst UpgradeGap UpBBIOBridgeBio Pharma4.1822 of 5 stars$51.96+3.8%$63.94+23.1%+116.4%$9.57B$221.90M-12.70400MRNAModerna4.3307 of 5 stars$25.33+3.4%$41.81+65.1%-54.3%$9.53B$3.24B-3.365,800VRNAVerona Pharma PLC American Depositary Share1.9064 of 5 stars$106.61-0.1%$109.00+2.2%+234.0%$9.20B$42.28M-107.6930Positive NewsRVMDRevolution Medicines4.2767 of 5 stars$46.07+4.9%$74.64+62.0%-1.6%$8.21B$11.58M-10.24250GRFSGrifols3.7816 of 5 stars$9.93+1.1%$10.30+3.7%+7.7%$6.75B$7.81B8.4923,822Short Interest ↑ Related Companies and Tools Related Companies SLNO Competitors VTRS Competitors ROIV Competitors QGEN Competitors ELAN Competitors BBIO Competitors MRNA Competitors VRNA Competitors RVMD Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
